Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (261-270 of 325) with videos related to

Pageof 33
Sort By:
American Journal of Hematology|September 24, 2017
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findingsPaul J Hampel, Kari G Chaffee, Rebecca L King, et al.
American Journal of Hematology|April 13, 2020
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic indexGeffen Kleinstern, Daniel R O'Brien, Xing Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Genetic susceptibility variants for chronic lymphocytic leukemiaSusan L Slager, Lynn R Goldin, Sara S Strom, et al.
The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.
Leukemia|April 20, 2022
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activityMichelle J Cox, Claudia Manriquez Roman, Erin E Tapper, et al.
Cancer Medicine|March 19, 2020
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practiceSameer A Parikh, Sara J Achenbach, Timothy G Call, et al.
American Journal of Hematology|March 22, 2021
The prognostic significance of del6q23 in chronic lymphocytic leukemiaHadiyah Y Audil, Paul J Hampel, Daniel L Van Dyke, et al.
Blood Advances|August 20, 2024
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
British Journal of Haematology|July 15, 2025
The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosisSamuel Kosydar, William J Archibald, Paul J Hampel, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Pageof 33

Showing results (261-270 of 325) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|September 24, 2017
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findingsPaul J Hampel, Kari G Chaffee, Rebecca L King, et al.
American Journal of Hematology|April 13, 2020
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic indexGeffen Kleinstern, Daniel R O'Brien, Xing Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Genetic susceptibility variants for chronic lymphocytic leukemiaSusan L Slager, Lynn R Goldin, Sara S Strom, et al.
The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.
Leukemia|April 20, 2022
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activityMichelle J Cox, Claudia Manriquez Roman, Erin E Tapper, et al.
Cancer Medicine|March 19, 2020
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practiceSameer A Parikh, Sara J Achenbach, Timothy G Call, et al.
American Journal of Hematology|March 22, 2021
The prognostic significance of del6q23 in chronic lymphocytic leukemiaHadiyah Y Audil, Paul J Hampel, Daniel L Van Dyke, et al.
Blood Advances|August 20, 2024
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
British Journal of Haematology|July 15, 2025
The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosisSamuel Kosydar, William J Archibald, Paul J Hampel, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Pageof 33